Cipla, one of India’s leading pharmaceutical companies, may soon join hands with a foreign company. Through this, she will work on the COVID vaccine ecosystem.
Cipla will expand COVID medicines
Cipla, one of the top 3 pharmaceutical companies in India, had launched a large number of COVID related medicines and diagnostic kits in the market during the pandemic. During this, the company also received revenue of about Rs 20,000 crore. Now Cipla is planning to partner with foreign companies for coronavirus vaccines.
Cipla, which made around 74% profit through Covid drugs (tocilizumab, remdesivir and azithromycin) in May. Keeping this in mind, the company has made up its mind to work on the vaccine ecosystem, for which it has also got approval from the government. In an interview to TOI, the company’s MD and Global CEO Umang Vohra said, “We are ready for partnership and have the resources and capacity to sell the vaccine. This will be done through our network hospitals. We have enough cold storage.” He also said that the company has no immediate plans to develop a COVID jab. There is speculation that Cipla has sought fast-track regulatory approval for US firm Moderna’s launch of the vaccine to bolster the country’s vaccine supply.
The company entered the diagnostics space with the COVID kit in October last year. Now it is planning to expand its COVID portfolio. However, no disclosure has been made by the company regarding the details or partnership of the foreign firm. Cipla had partnered with CSIR-IICT, a national level research center, to develop and launch Favipiravir, to distribute MSD’s antiviral drug Molnupiravir.
Also read: Post Office Scheme: You can get 14 lakhs by saving 95 rupees daily, these will also be benefits, know how to invest
Do these 5 things while investing in SIP, profits can be double
.